Synthetic triterpenoids can protect against toxicity without reducing the efficacy of treatment with carboplatin and paclitaxel in experimental lung cancer

Dose-Response

Volumn 12, Issue 1, 2014, Pages 136-151

  Liby, Karen T ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Carboplatin toxicity; CDDO methyl ester; Lung cancer; Nrf2; Reactive oxygen species; Triterpenoid

Indexed keywords

BARDOXOLONE ETHYL AMIDE; BARDOXOLONE IMIDAZOLIDE; BARDOXOLONE METHYL; CARBOPLATIN; PACLITAXEL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR NRF2; TRITERPENOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME INDUCTION; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN INDUCTION; TUMOR VOLUME;

EID: 84895447247     PISSN: None     EISSN: 15593258     Source Type: Journal    
DOI: 10.2203/dose-response.13-018.Liby     Document Type: Article

References (42)

1. Baird L and Dinkova-Kostova AT. 2011. The cytoprotective role of the keap1-nrf2 pathway. Arch Toxicol 85:241-272
2. Brookes PS, Morse K, Ray D, Tompkins A, Young SM, Hilchey S, Salim S, Konopleva M, Andreeff M, Phipps R and Bernstein SH. 2007. The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and its derivatives elicit human lymphoid cell apoptosis through a novel pathway involving the unregulated mitochondrial permeability transition pore. Cancer Res 67:1793-1802
3. Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, Mitsiades C, Munshi N, Tai YT, Suh N, Gribble GW, Honda T, Schlossman R, Richardson P, Sporn MB and Anderson KC. 2004. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma activity and overcome bortezomib resistance. Blood 103:3158-3166
4. Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW, Sporn MB and Talalay P. 2005. Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A 102:4584-4589
5. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA and Swanton C. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892
6. Hayes JD and McMahon M. 2009. Nrf2 and keap1 mutations: Permanent activation of an adaptive response in cancer. Trends Biochem Sci 34:176-188
7. Higgins LG, Kelleher MO, Eggleston IM, Itoh K, Yamamoto M and Hayes JD. 2009. Transcription factor nrf2 mediates an adaptive response to sulforaphane that protects fibroblasts in vitro against the cytotoxic effects of electrophiles, peroxides and redox-cycling agents. Toxicol Appl Pharmacol 237:267-280
8. Hill RA and Connolly JD. 2012. Triterpenoids. Nat Prod Rep 29:780-818
9. Honda T, Honda Y, Favaloro FG, Jr., Gribble GW, Suh N, Place AE, Rendi MH and Sporn MB. 2002. A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg Med Chem Lett 12:1027-1030
10. Honda T, Rounds BV, Bore L, Favaloro FG, Jr., Gribble GW, Suh N, Wang Y and Sporn MB. 1999. Novel synthetic oleanane triterpenoids: A series of highly active inhibitors of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 9:3429-3434
11. Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI and Dezube BJ. 2012. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res 18:3396-3406
12. Ikeda T, Nakata Y, Kimura F, Sato K, Anderson K, Motoyoshi K, Sporn M and Kufe D. 2004. Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid. Mol Cancer Ther 3:39-45
13. Ikeda T, Sporn M, Honda T, Gribble GW and Kufe D. 2003. The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. Cancer Res 63:5551-5558
14. Ito Y, Pandey P, Place A, Sporn MB, Gribble GW, Honda T, Kharbanda S and Kufe D. 2000. The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Differ 11:261-267
15. Ito Y, Pandey P, Sporn MB, Datta R, Kharbanda S and Kufe D. 2001. The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. Mol Pharmacol 59:1094-1099
16. Kensler TW and Wakabayashi N. 2010. Nrf2: Friend or foe for chemoprevention? Carcinogenesis 31:90-99
17. Kim EH, Deng CX, Sporn MB and Liby KT. 2011. Cddo-imidazolide induces DNA damage, G2/M arrest and apoptosis in brca1-mutated breast cancer cells. Cancer Prev Res 4:425-434
18. Liby K, Black CC, Royce DB, Williams CR, Risingsong R, Yore MM, Liu X, Honda T, Gribble GW, Lamph WW, Sporn TA, Dmitrovsky E and Sporn MB. 2008. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Mol Cancer Ther 7:1251-1257
19. Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A and Sporn MB. 2005. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and nrf2/are signaling. Cancer Res 65:4789-4798
20. Liby K, Risingsong R, Royce DB, Williams CR, Ma T, Yore MM and Sporn MB. 2009. Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. Cancer Prev Res 2:1050-1058
21. Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, Gribble GW, Dmitrovsky E, Sporn TA and Sporn MB. 2007. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res 67:2414-2419
22. Liby KT and Sporn MB. 2012. Synthetic oleanane triterpenoids: Multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev 64:972-1003
23. Miller FR. 2000. Xenograft models of premalignant breast disease. J Mammary Gland Biol Neoplasia 5:379-391
24. Pauley RJ, Soule HD, Tait L, Miller FR, Wolman SR, Dawson PJ and Heppner GH. 1993. The MCF10 family of spontaneously immortalized human breast epithelial cell lines: Models of neoplastic progression. Eur J Cancer Prev 2 Suppl 3:67-76
25. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J and Warnock DG. 2011. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365:327-336
26. Pitha-Rowe I, Liby K, Royce D and Sporn M. 2009. Synthetic triterpenoids attenuate cytotoxic retinal injury: Cross-talk between nrf2 and pi3k/akt signaling through inhibition of the lipid phosphatase pten. Invest Ophthalmol Vis Sci 50:5339-5347
27. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordonez GR, Bignell GR, Ye K, Alipaz J, Bauer MJ, Beare D, Butler A, Carter RJ, Chen L, Cox AJ, Edkins S, Kokko-Gonzales PI, Gormley NA, Grocock RJ, Haudenschild CD, Hims MM, James T, Jia M, Kingsbury Z, Leroy C, Marshall J, Menzies A, Mudie LJ, Ning Z, Royce T, Schulz-Trieglaff OB, Spiridou A, Stebbings LA, Szajkowski L, Teague J, Williamson D, Chin L, Ross MT, Campbell PJ, Bentley DR, Futreal PA and Stratton MR. 2010. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463:191-196
28. Prior IA, Lewis PD and Mattos C. 2012. A comprehensive survey of ras mutations in cancer. Cancer Res 72:2457-2467
29. Pylayeva-Gupta Y, Grabocka E and Bar-Sagi D. 2011. Ras oncogenes: Weaving a tumorigenic web. Nat Rev Cancer 11:761-774
30. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, Stern AM, Mandinova A, Schreiber SL and Lee SW. 2011. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475:231-234
31. Ruiz S, Pergola PE, Zager RA and Vaziri ND. 2013. Targeting the transcription factor nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int 83:1029-1041
32. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, Wolman SR, Heppner GH and Miller FR. 2001. Malignant MCF10ca1 cell lines derived from premalignant human breast epithelial MCF10at cells. Breast Cancer Res Treat 65:101-110
33. Sporn MB. 2006. Dichotomies in cancer research: Some suggestions for a new synthesis. Nat Clin Pract Oncol 3:364-373
34. Sporn MB and Liby KT. 2012. Nrf2 and cancer: The good, the bad and the importance of context. Nat Rev Cancer 12:564-571
35. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM and Gribble GW. 2011. New synthetic triterpenoids: Potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J Nat Prod 74:537-545
36. Strickland LB, Dawson PJ, Santner SJ and Miller FR. 2000. Progression of premalignant MCF10at generates heterogeneous malignant variants with characteristic histologic types and immunohistochemical markers. Breast Cancer Res Treat 64:235-240
37. Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, Hickey WF, Maue RA, Place AE, Porter DM, Spinella MJ, Williams CR, Wu G, Dannenberg AJ, Flanders KC, Letterio JJ, Mangelsdorf DJ, Nathan CF, Nguyen L, Porter WW, Ren RF, Roberts AB, Roche NS, Subbaramaiah K and Sporn MB. 1999. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res 59:336-341
38. Trachootham D, Alexandre J and Huang P. 2009. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 8:579-591
39. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J and Huang P. 2006. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10:241-252
40. Watson J. 2013. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol 3:120144
41. Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, Gribble GW, Johnson DA, Johnson JA, Burton NC, Guilarte TR, Yamamoto M, Sporn MB and Kensler TW. 2007. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of nrf2-regulated genes. Mol Cancer Ther 6:154-162
42. You M, Candrian U, Maronpot RR, Stoner GD and Anderson MW. 1989. Activation of the ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain a mouse. Proc Natl Acad Sci U S A 86:3070-3074